NASDAQ
4.66USD
0.00 (0.00%)
We have scored 3 news catalysts on CureVac N.V. (CVAC) over the past 12 months. The biggest single-day move next to one of them came Nov 26, 2025, when CVAC closed +3.8%: “BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration”. Coverage across the window leans positive (average ticker sentiment +0.37). Most of the impact sits in short squeeze potential and sector technology.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1B
P/E
—
EPS
—
Beta
1.84
52W range
2.475-5.72
Day range
4.57–4.66
Open
4.57
Prev close
4.66
Volume
728.8K
Avg volume
1.2M
Dividend
0.00
IPO
2020-08-14
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CureVac N.V. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of CureVac N.V., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for CVAC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.
